user Admin_Adham
6th Aug, 2026 12:00 AM
Test

Amazon Pharmacy Offers Weight-loss Drugs for $50 a Month Through Medicare Bridge Program

Aug 6 (Reuters) - Amazon's pharmacy unit said on Thursday it would offer weight-loss drugs to eligible Medicare beneficiaries for $50 a ⁠month through a new federal program created to expand access to the highly sought-after treatments.

The company said it would ⁠automate eligibility checks, prior authorization and billing, while offering home delivery and in-store pickup, to help patients ⁠access the drugs faster and ‌reduce the administrative burden.

• The U.S. government's Medicare bridge program, launched last month, allows eligible beneficiaries to obtain drugs including Novo Nordisk's Wegovy in injection or pill form, as well as Eli Lilly's four-dose Zepbound KwikPen injection and the Foundayo pill, through the end of ‌2027. The program does not cover single-dose Zepbound vials or pens.

• Amazon ​Pharmacy said ‌it would initiate the enrolment process ‌on a customer's behalf once the patient adds insurance and Medicare details to their account and a clinician ⁠submits an electronic prescription.

• Most Amazon Pharmacy Bridge Program ‌patients received a prior ⁠authorization decision in less than ​24 hours, compared with the 72-hour timeframe ‌allowed under the Medicare Bridge Program, Tanvi Patel, vice president and general manager of Amazon Pharmacy, told Reuters.

SUGGESTED FOR YOU

• Many of the claims submitted have already resulted in completed ​orders, the company added.

• Amazon Pharmacy launched electronic kiosks in ‌its ‌One Medical primary care locations last year to improve access and cut shipping costs.

• One ‌Medical, a national primary ​care provider Amazon acquired in 2023, allows patients to access primary and urgent care for an annual subscription fee of $199.

• Same-day delivery is available in more ⁠than 3,100 U.S. cities and towns and is expected to expand ‌to nearly 4,500 locations by the end of 2026, Amazon said.

(Reporting by Sahil ​Pandey in Bengaluru; Editing by Jonathan Ananda)


Share This Article

Comments

Leave a comment